Lista de obras - Ruth Lopert - Dominio Público Uruguay

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate

artículo científico publicado en 2015

A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study

scientific article published on 01 July 1997

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs.

artículo científico publicado en 2015

Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children ⬇️

artículo científico publicado el 7 de octubre de 2010

Biosimilars and the European experience: implications for the United States

artículo científico publicado en 2013

Child influenza vaccination. Panvax febrile reactions not a predictor

scientific article published on 21 July 2010

Comparative effectiveness research and evidence-based health policy: experience from four countries

artículo científico publicado en 2009

Costs of new treatments for hepatitis C infection

artículo científico publicado en 2014

Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership Agreement.

artículo científico

Differential pricing of drugs: a role for cost-effectiveness analysis?

artículo científico publicado en 2002

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

artículo científico

Does Medication Adherence Lower Medicare Spending among Beneficiaries with Diabetes? ⬇️

artículo científico publicado el 17 de marzo de 2011

Drug-induced delirium. Incidence, management and prevention.

artículo científico publicado en 1996

Faecal microbiota transplantation: a sui generis biological drug, not a tissue.

artículo científico publicado en 2014

How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand ⬇️

artículo científico publicado el 30 de agosto de 2013

Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process

scientific article published on 28 November 2019

International Price Comparisons for Novel and Follow-on Drugs: A Response

Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program.

artículo científico publicado en 2013

Medication adherence and Medicare expenditure among beneficiaries with heart failure

artículo científico publicado el 1 de septiembre de 2012

Medication information for patients with limited English proficiency: lessons from the European Union.

artículo científico publicado en 2012

PBS copayments and safety nets

scientific article published on 01 May 2009

Pharma's next frontier? New threats to public health in the Regional Comprehensive Economic Partnership agreement

artículo científico publicado en 2015

Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States

artículo científico publicado en 2007

Reply by authors

artículo científico publicado en 2014

Revolution then evolution: the advance of health economic evaluation in Australia

artículo científico publicado en 2014

Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes ⬇️

artículo científico publicado el 10 de abril de 2012

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

artículo científico publicado en 2016

The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.

artículo científico publicado en 2016

The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam

artículo científico publicado en 2016

The high price of "free" trade: U.S. trade agreements and access to medicines.

artículo científico publicado en 2013

Toward a definition of pharmaceutical innovation ⬇️

artículo científico publicado el 30 de enero de 2008

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

artículo científico

Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin

artículo científico publicado en 2003

Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.

artículo científico publicado en 2003

What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia.

artículo científico publicado en 2007

Willingness to pay for cancer therapy

artículo científico publicado en 2012

Lista de obras de Ruth Lopert

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate

A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs.

Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children ⬇️

Biosimilars and the European experience: implications for the United States

Child influenza vaccination. Panvax febrile reactions not a predictor

Comparative effectiveness research and evidence-based health policy: experience from four countries

Costs of new treatments for hepatitis C infection

Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership Agreement.

Differential pricing of drugs: a role for cost-effectiveness analysis?

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

Does Medication Adherence Lower Medicare Spending among Beneficiaries with Diabetes? ⬇️

Drug-induced delirium. Incidence, management and prevention.

Faecal microbiota transplantation: a sui generis biological drug, not a tissue.

How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand ⬇️

Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process

International Price Comparisons for Novel and Follow-on Drugs: A Response

Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program.

Medication adherence and Medicare expenditure among beneficiaries with heart failure

Medication information for patients with limited English proficiency: lessons from the European Union.

PBS copayments and safety nets

Pharma's next frontier? New threats to public health in the Regional Comprehensive Economic Partnership agreement

Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States

Reply by authors

Revolution then evolution: the advance of health economic evaluation in Australia

Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes ⬇️

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.

The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam

The high price of "free" trade: U.S. trade agreements and access to medicines.

Toward a definition of pharmaceutical innovation ⬇️

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin

Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.

What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia.

Willingness to pay for cancer therapy